Skip to main content

Advertisement

SpringerLink
Log in

ADORE – Attention–Deficit Hyperactivity Disorder Observational Research in Europe

  • ORIGINAL CONTRIBUTION
  • Published:
European Child & Adolescent Psychiatry Aims and scope Submit manuscript

Abstract

Background

Since there is little information about the naturalistic way of treatment in daily European practice, the Attention–Deficit Hyperactivity Disorder Observational Research in Europe (ADORE) project was designed as a prospective, non–interventional study of approximately 1,500 patients observed by approximately 300 investigators in various European regions.

Objective

The primary objective is the description of the relationship between treatment regimen prescribed and quality of life in ADHD patients over a two–year period.

Method

The naturalistic care provided and the outcomes (psychopathology, quality of life) are recorded at 7 data collection points.

Results

The present preliminary report provides data on the first 315 patients who were included in the study by the beginning of January 2004. The data provide an impression of the sample characteristics, the clinical diversity, and the effects of ADHD on school careers and social activities. Furthermore, treatment information dealing with the time both before and at baseline is given.

Conclusion

Even with this limited sample the negative effects on psychosocial development and quality of life in ADHD children are apparent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Buitelaar JK (2002) Epidemiological aspects: what have we learned over the last decade? In: Sandberg S (ed) Hyperactivity and Attention Disorder of Childhood. Cambridge University Press, Cambridge

  2. Buitelaar JK, Montgomery SA, van Zwieten- Boot BJ, on behalf of the Consensus Committee Brown T, Findling RL, Gillberg C, Lecrubier Y, Saint Raymond A, Spencer T, Steinhausen HC (2003) Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological intervention. Eur Neuropsychopharmacol 13:297–304

    CAS  PubMed  Google Scholar 

  3. Danckaerts M, Heptinstall E, Chadwick O, Taylor E (1999) Self-report of attention deficit and hyperactivity disorder in adolescents. Psychopathology 32:81–92

    Article  CAS  PubMed  Google Scholar 

  4. Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie (eds) (2000) Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter. Deutscher Ärzte Verlag, Koeln

  5. DuPaul GJ, Power TJ, et al. (1988) ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. The Guilford Press, New York

  6. Goodman R (1997) The Strengths and Difficulties Questionnaire: a research note. J Child Psychol Psychiatry 38:581–586

    CAS  PubMed  Google Scholar 

  7. Guy, W (ed) (1976) Clinical Global Impressions. In ECDEU Assessment Manual for Psychopharmacology, revised. National Institute of Mental Health, Rockville MD

  8. Klasen H, Goodman R (2000) Parents and GPs at cross-purposes over hyperactivity: a qualitative study of possible barriers to treatment. Br J Gen Pract 50:199–202

    CAS  PubMed  Google Scholar 

  9. Nederlandse Vereniging voor Psychiatrie en Sectie Kinder- en Jeugdpsychiatrie (NVP) (1999) Richtlijn diagnostiek en behandeling ADHD (kinderen en adolescenten). Uitgeverij Boom, Bestuur Nederlandse Vereniging voor Psychiatrie Amsterdam

  10. Riley AW, Forrest C, Starfield B, Rebok G, Green B, Robertson J (2001) Child Health and Illness Profile – Child Edition (CHIP-CE™). The John Hopkins University, Baltimore MD

  11. Sergeant J, Steinhausen HC (1992) European perspectives on hyperkinetic disorder. Eur Child Adolesc Psychiatry 1:34–41

    Google Scholar 

  12. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S (1983) A children’s global assessment scale (C- GAS). Arch Gen Psychiatry 40:1228–1231

    PubMed  Google Scholar 

  13. Steinhausen HC, Metzke CW, Meier M, Kannenberg R (1998) Prevalence of child and adolescent psychiatric disorders: the Zurich Epidemiological Study. Acta Psychiatr Scand 98:262–271

    CAS  PubMed  Google Scholar 

  14. Swanson JM, Sergeant J, Taylor E, Sonuga-Barke E, Jensen P, Cantwell DP ( Swanson) Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet 351:429–433

    Google Scholar 

  15. Taylor E, Döpfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC, Zuddas A (2004) European clinical guidelines for hyperkinetic disorder – first upgrade. Eur Child Adolesc Psychiatry 13:I7–I30

    Google Scholar 

  16. Taylor E, Chadwick O, Heptinstall E, Danckaerts M (1996) Hyperactivity and conduct problems as risk factors for adolescent development. J Am Acad Child Adolesc Psychiatry 35:1213–1226

    CAS  PubMed  Google Scholar 

  17. Taylor E, Sandberg S, Thorley G, Giles S (1991) The epidemiology of childhood hyperactivity. Maudsley Monographs No. 33. Institute of Psychiatry, London

  18. Taylor E, Sergeant J, Döpfner M, Gunning B, Overmeyer S, Möbius HJ, Eisert HG (1998) Clinical guidelines for hyperkinetic disorder. Eur Child Adolesc Psychiatry 7:184–200

    PubMed  Google Scholar 

  19. Verhulst FC, van der Ende J, Ferdinand RF, Kasius MC (1997) The prevalence of DSM-III-R diagnoses in a national sample of Dutch adolescents. Arch Gen Psychiatry 54:329–336

    CAS  PubMed  Google Scholar 

  20. Woodward L, Dowdney L, Taylor E (1997) Child and family factors influencing the clinical referral of children with hyperactivity: a research note. J Child Psychol Psychiatry 38:479–485

    CAS  PubMed  Google Scholar 

  21. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T; Atomoxetine ADHD Study Group (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomised placebo-controlled, dose response study. Pediatrics 108 (5):E83

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Eli Lilly and Company, Lilly Research Centre Erl Wood Manor Windlesham, Surrey GU20PH, UK

    Stephen J. Ralston Ba (Hons), MSc. & M. J. M. Lorenzo

Authors
  1. Stephen J. Ralston Ba (Hons), MSc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. J. M. Lorenzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

and the ADORE study group

Corresponding author

Correspondence to Stephen J. Ralston Ba (Hons), MSc..

Additional information

Members of the ADORE study group: Baldursson G, Coghill D, Curatolo P, Dalsgaard S,Döpfner M,Falissard B,Forrest CB,Hervas A, Le Heuzey MF, Lorenzo MJM, Nøvik TS, Pereira RR, Preuss U, Rasmussen P, Rothenberger A, Riley AW, Spiel G, Steinhausen HC, Vlasveld L. The ADORE study has the financial support of Eli Lilly and Company Limited.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ralston, S.J., Lorenzo, M.J.M. & and the ADORE study group. ADORE – Attention–Deficit Hyperactivity Disorder Observational Research in Europe. European Child & Adolescent Psychiatry 13 (Suppl 1), i36–i42 (2004). https://doi.org/10.1007/s00787-004-1004-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00787-004-1004-8

Keywords

Search

Navigation